Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT)

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2023
This article has no abstract
Epistemonikos ID: ff037f7ff60024b0c3f35eee26b203d3d53bef03
First added on: Jan 23, 2025